News
Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...
Officials in Ruidoso, New Mexico will hold a press conference following the three deaths reported due to floods on Tuesday.
9d
Zacks Investment Research on MSNVor Bio Stock Skyrockets 250% in the Past Week: Here's WhyShares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, ...
13d
InvestorsHub on MSNVor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune TherapyVor Biopharma Inc. (NASDAQ:VOR) saw its stock surge by 85% after unveiling a major licensing agreement with RemeGen Co., Ltd.
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...
The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...
Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset.
Warburg Pincus steht kurz vor der Übernahme einer Mehrheitsbeteiligung an der Uvex Group, dem Fürther Hersteller von ...
Die Europäische Union könnte nach Einschätzung von Frankreichs Finanzminister Eric Lombard noch vor dem 9. Juli ein ...
See the latest Vor Biopharma Inc Ordinary Shares stock price (VOR:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results